Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Immunitybio - The Real Truth

FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong

Federal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs

The Independent UK

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments

Iovance and ImmunityBio have doubled and quadrupled in share price so far this year, respectively, thanks to powerful cancer medicines that could upend care.

Small Caps Can Only Lead Stocks So High: Stock Market Today

Small Caps Can Only Lead Stocks So High: Stock Market Today

The main U.S. equity indexes were down for the week, but small-cap stocks look as healthy as they ever have.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Biotech Breakouts: 3 Stocks With Massive Upside Potential

Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential

What's Going On With ImmunityBio Shares Tuesday?

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

Billionaire Soon-Shiong bets Africa is cure for flatlined stock

At this time a year ago, investors saw billionaire Patrick Soon-Shiong’s biotech company ImmunityBio Inc. as a moonshot that would make them rich.

Tribune News Service

inkl

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program

Here's a roundup of top developments in the biotech space over the last 24 hours:

ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial

ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial

ImmunityBio Inc (NASDAQ: IBRX) has

The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data

The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

1

People

182,659 stories

Patrick SoonShiong

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Uber Technologies

CF Industries Holdings

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play